Skip to main content
Cancer Explained
Donate
Beginner 6 min readSource checked

Kidney Cancer Survival Rates and What They Really Mean

What NCI's SEER data on kidney cancer survival means, and doesn't mean, for someone newly diagnosed.

This is general education — it cannot tell you what to do in your situation.

Instructions and urgent-contact thresholds vary by treatment and care team. If you are in treatment, follow the instructions your oncology team gave you, and contact them about any new or worsening symptom. If you think you may be having a medical emergency, call your local emergency number.

NCI source

National Cancer Institute SEER Cancer Stat Facts: Kidney and Renal Pelvis Cancer

A man holds his throat while talking with a female doctor in an exam room
A man holds his throat while talking with a female doctor in an exam room

Key fact

A survival statistic describes a large group diagnosed years ago — not a prediction for any one person.

The short answer

SEER reports a 79.2% five-year relative survival rate for kidney and renal pelvis cancer overall. Localized kidney cancer is 93.6%; distant (metastatic) disease is 20.3%. Kidney cancer is often found incidentally on imaging done for another reason, which helps many cases get caught early.

  • A survival statistic describes a large group diagnosed years ago — not a prediction for any one person.

  • For kidney cancer, the five-year relative survival rate for everyone combined, diagnosed 2016–2022, was 79.2%.

  • Stage at diagnosis makes a large difference: localized disease is 93.6% versus 20.3% for distant (metastatic) disease.

  • Many kidney cancers are found incidentally on imaging, before symptoms appear.

Choose how you want to understand this

The full explanation.

Before you look at the numbers

Three things are true about the numbers below. Read them before you read a single percentage.

First, a "5-year relative survival rate" for kidney cancer describes a large group of people. Those people were diagnosed with kidney cancer years ago. It is not a prediction about you. Everyone's kidney cancer, body, and treatment plan are different.

Second, this data lags behind today's care. These figures reflect people diagnosed with kidney cancer between 2016 and 2022. Targeted drugs and immunotherapy combinations for advanced kidney cancer have kept being refined since then. So kidney cancer treatment today may already work better than these numbers suggest.

Third, an all-stages number blends very different people together. It mixes people with early, easy-to-treat cancer with people whose cancer had already spread. For kidney cancer, the stage-specific numbers below beat one blended average. And "5-year" is just a measurement window researchers use for consistency. It is not a life expectancy for anyone with kidney cancer. It is not a deadline either.

The SEER numbers for kidney cancer

SEER's most recent report covers people diagnosed with kidney and renal pelvis cancer between 2016 and 2022. Across every stage combined, the five-year relative survival rate was 79.2%. About two-thirds of kidney cancers are found at the localized stage.

Kidney cancer is often found by chance. A scan done for an unrelated reason picks it up before it causes symptoms.

Stage at diagnosis5-year relative survival
Localized — confined to the kidney93.6%
Regional — spread to nearby lymph nodes77.6%
Distant — spread to other parts of the body20.3%
Unknown/unstaged55.2%

What "relative survival" actually means

Relative survival compares two groups. One is people with kidney cancer. The other is people in the general population who are the same age and sex but do not have cancer. Say the relative survival rate is 100%. That means people with the cancer were, as a group, about as likely to be alive at 5 years as people without it. It is not the same as the share of people who are cancer-free. And it is not the share of people who die from the cancer itself.

Kidney cancer includes several histologic subtypes, meaning types defined by how the cells look. The most common is clear cell renal cell carcinoma. These subtypes behave differently from each other. Advanced kidney cancer is now often treated with combinations of immunotherapy and targeted drugs. That area has changed a lot in recent years.

What actually changes your outlook

A statistic describes a group. Your own outlook depends on things specific to you:

  • Stage — how far the kidney cancer has spread, as shown in the table above.
  • Grade — how abnormal the cancer cells look under a microscope, and how fast they tend to grow.
  • Histologic subtype — clear cell, papillary, and other subtypes of kidney cancer can behave differently.
  • Tumor grade — how abnormal the cells look, which affects how the cancer is expected to behave.
  • How your cancer responds to treatment — early scans and lab results often tell your care team more than the statistics at diagnosis do.
  • Your overall health — other medical conditions, age, and general fitness all affect treatment options and recovery.
  • Access to care — timely diagnosis, specialist care, and the ability to complete treatment all matter.

Questions for your care team

  • Which SEER stage describes my kidney cancer, and what is its five-year number?
  • Which biomarkers or molecular tests matter in kidney cancer, and were they run on my sample?
  • How do my age and overall health change these kidney cancer statistics for me?
  • Are there newer kidney cancer treatments available now that this data doesn't reflect yet?
  • Beyond the general kidney cancer statistics, what does my team expect in my case?
  • Where can I find support for how it feels to hear these kidney cancer numbers?
  • What histologic subtype and grade is my kidney cancer, and how does that affect my outlook?

If these numbers are hard to sit with

You may feel scared, numb or overwhelmed after reading survival statistics. That is a normal reaction. It does not mean you are handling a kidney cancer diagnosis the wrong way. Many people find it easier to take these numbers in slowly, with someone else in the room. Others skip the numbers altogether until they are ready. Cancer Anxiety and Uncertainty covers the fear these kidney cancer numbers can stir up. It is also worth telling your kidney cancer team how much detail you want, and when.

Sources

Words to know

Tap any term to see what it means.

Browse the full glossary →

An older Black man talks with a woman in a cozy, lamp-lit living room

Common questions

What does 79.2% five-year relative survival mean for kidney cancer?

It means that, on average, people diagnosed with kidney cancer between 2016 and 2022 were about 79.2% as likely to be alive 5 years later as people of the same age and sex without kidney cancer. It blends every stage together, from early to advanced.

Why is the stage-specific number so different from the overall number?

The overall number blends people found early, when kidney cancer is most treatable, with people found later. Stage makes a large difference — see the table above. Localized kidney cancer usually has a much higher five-year relative survival than distant (metastatic) disease.

Does this number predict what will happen to me?

No. This is a statistic about a large group of people, not a prediction about you. Your age, overall health, tumor biology, and how your kidney cancer responds to treatment all shape your individual outlook in ways a group statistic cannot capture.

Is this the most current data available?

It is the most recent data SEER has published, but it still reflects people diagnosed in 2016–2022. Treatments keep changing, so people diagnosed today may do better than these numbers suggest.

Why was my kidney cancer found before I had any symptoms?

Kidney cancer is often found incidentally, on an ultrasound or CT scan done for an unrelated reason. This is one reason localized kidney cancer is diagnosed so often, and why its overall survival numbers are relatively high compared to cancers usually found after symptoms appear.

Questions to ask your doctor

Being prepared helps you get the most out of your appointments. Save or print these questions.

Open my question list

Tap a question to save it to your list (kept on this device).

Human Connection Layer

Speak With Trained Specialists & Human Navigators

Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.

Free & Confidential

Talk to a trained cancer information specialist

Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.

Contact your oncology team

Locate after-hours contact numbers, portal messages, or urgent triage phone lines.

Find a patient navigator

Get one-on-one help with appointments, logistics, translation, and care coordination.

Find a genetic counselor

Discuss inherited mutation risk, family history, and genetic testing options.

Find an oncology social worker

Access emotional counseling, family support groups, and mental health resources.

Find a financial navigator

Locate copay assistance foundations, grant programs, and lodging/travel support.

Find a clinical-trial specialist

Search matching studies and speak with NCI trial information specialists.

Get urgent help

Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.

Help Us Improve This Guide

Did this explanation answer your question and help you determine your next step?

Know someone who needs this?

Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.

Email itText itWhatsApp

Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.

Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.

Last updated: 2026-08-17Next planned review: 2027-08-03

How this page was created

Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.

Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.

High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.

Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.

Our editorial processHow we use AIReport an error

How this page was created

Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.

Editorial status: Source checked This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.

Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.

Read more about our editorial process, our use of AI, and our corrections policy.

Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.

After using this page, do you understand what to do next?

Anonymous — we only record the answer, never who gave it.